EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Sustained glucagon‐like peptide‐1 receptor agonist treatment improves glycemic control and reduces all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitors: A real‐world target trial emulation in type 2 diabetes

Dauerhafte Behandlung mit GLP-1-Rezeptoragonisten verbessert die glykämische Kontrolle und senkt die Gesamtmortalität im Vergleich zu DPP-4-Inhibitoren: eine Real-World-Target-Trial-Emulation bei Typ-2-Diabetes

Kathrine Kold Sørensen iD, Puriya Daniel Würtz Yazdanfard, Bochra Zareini, Hannah Karin Wood-Kurland, Ulrik Pedersen-Bjergaard iD, Mikkel Porsborg Andersen, Jens Michelsen, Henrik Imberg, Marcus Lind, Sara Hallström, Stefanie Lanzinger iD, Anders Munch und 4 weitere

Diabetes, Obesity and Metabolism · 2026-05 · 28 (5) · 3974-3984

DOI: 10.1111/dom.70581 ↗

Auf einen Blick

Bei Menschen mit Typ-2-Diabetes war eine dauerhafte GLP-1-RA-Therapie mit besserer HbA1c-Verbesserung und geringerer Gesamtmortalität verbunden als DPP-4-Inhibitoren.

Fragestellung

Wie wirksam ist eine dauerhafte GLP-1-RA-Anwendung im Vergleich zu DPP-4-Inhibitoren in der Routineversorgung hinsichtlich HbA1c-Verbesserung und Mortalität?

Methode

Target-Trial-Emulation mit dänischen Registerdaten (2012–2022); Vergleich von GLP-1-RAs mit DPP-4is; Analyse mit Longitudinal Targeted Minimum Loss-based Estimation.

Ergebnisse

16 619 GLP-1-RA- und 34 196 DPP-4i-Initierende. Nach 1 Jahr: HbA1c-Verbesserung 82,7 % (95 %-KI 82,0 %–83,4 %) vs. 67,1 % (95 %-KI 66,5 %–67,6 %); absolute Differenz 15,7 % (95 %-KI 14,8 %–16,5 %).

Einschränkungen

Limitations of this nationwide study and the available data.

Schlussfolgerung der Autor:innen

Nach Ansicht der Autor:innen zeigte die dauerhafte GLP-1-RA-Therapie eine überlegene glykämische Kontrolle und war mit einem moderaten Mortalitätsvorteil gegenüber DPP-4i verbunden.

Kernaussagen

  • HbA1c-Verbesserung nach 1 Jahr häufiger unter GLP-1-RA
  • Absolute Differenz 15,7 % (95 %-KI 14,8 %–16,5 %)
  • Gesamtmortalität unter GLP-1-RA geringer

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 25.02.2026. Verfasst von Kathrine Kold Sørensen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Copenhagen University Hospital, Steno Diabetes Center Copenhagen, Herlev, Denmark. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Glycemic Control. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Union, European Commission.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glucagon‐like peptide 1 receptor agonists (GLP‐1 RAs) improve glycemic outcomes in people with type 2 diabetes, but their generalizability to routine clinical practice remains uncertain.

Aim

To evaluate the real‐world effectiveness of sustained GLP‐1 RA use on haemoglobin A1c (HbA1c) over 1 to 4.5 years, using dipeptidyl peptidase 4 inhibitors (DPP‐4is) as an active comparator.

Methods

Using Danish nationwide registries (2012–2022), we emulated a target trial assessing the glycemic effectiveness of GLP‐1 RAs. The primary outcome was the probability of improvement in defined HbA1c categories within 1 year. Longitudinal Targeted Minimum Loss‐based Estimation was used to estimate the primary outcome under sustained use of GLP‐1 RA and DPP 4i, controlling for baseline and time‐varying confounding.

Results

We included 16 619 GLP‐1 RA initiators and 34 196 DPP‐4i initiators, each with 2.8 HbA1c measurements per patient‐year. At 1 year, the probability of any HbA1c improvement was 82.7% (95% CI: 82.0% to 83.4%) under sustained GLP‐1 RA versus 67.1% (95% CI: 66.5% to 67.6%) under DPP‐4i, an absolute difference of 15.7% (95% CI: 14.8% to 16.5%). GLP‐1 RA treatment was also associated with a lower all‐cause mortality risk, with absolute reductions of 0.4% (95% CI: 0.1% to 0.7%) at 1 year and 1.1% (95% CI: 0.3% to 2.0%) at 3 years.

Conclusion

Within the limitations of this nationwide study and the available data, sustained GLP‐1 RA therapy provided superior glycemic control and was associated with a modest mortality benefit compared with DPP‐4i therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsGlycemic ControlHypoglycemic AgentsHumansMaleFemaleGlycated HemoglobinMiddle AgedAgedDenmarkBlood GlucoseTreatment Outcome

Stichwörter der Autor:innen

GLP‐1 analogueantidiabetic drugcohort studyglycaemic controlreal‐world evidence

Substanzen

Dipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsGlycated HemoglobinHypoglycemic Agentshemoglobin A1c protein, humanBlood Glucose

Autor:innen und Institutionen

  • Copenhagen University Hospital, Steno Diabetes Center Copenhagen, Herlev, Denmark.
  • Department of Endocrinology and Nephrology, North Zealand University Hospital, Hillerød.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • The Prehospital Center, Region Zealand, Næstved, Denmark.
  • Department of Health Science and Technology, Aalborg University, Aalborg, Denmark.
  • Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

ORCID-Profile: Kathrine Kold Sørensen, Ulrik Pedersen-Bjergaard, Stefanie Lanzinger

Förderung

  • European Union
  • European Commission

Zitieren

APA

Sørensen, K. K., Yazdanfard, P. D. W., Zareini, B., Wood-Kurland, H. K., Pedersen-Bjergaard, U., Andersen, M. P., Michelsen, J., Imberg, H., Lind, M., Hallström, S., Lanzinger, S., Munch, A., Ohlendorff, J. S., Gerds, T. A., Torp-Pedersen, C., & REDDIE Consortium (2026). Sustained glucagon‐like peptide‐1 receptor agonist treatment improves glycemic control and reduces all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitors: A real‐world target trial emulation in type 2 diabetes. Diabetes, Obesity and Metabolism, 28(5), 3974-3984. https://doi.org/10.1111/dom.70581

Vancouver

Sørensen KK, Yazdanfard PDW, Zareini B, Wood-Kurland HK, Pedersen-Bjergaard U, Andersen MP, et al. Sustained glucagon‐like peptide‐1 receptor agonist treatment improves glycemic control and reduces all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitors: A real‐world target trial emulation in type 2 diabetes. Diabetes, Obesity and Metabolism. 2026;28(5):3974-3984. doi:10.1111/dom.70581

BibTeX
@article{Srensen2026,
  author = {Sørensen, Kathrine Kold and Yazdanfard, Puriya Daniel Würtz and Zareini, Bochra and Wood-Kurland, Hannah Karin and Pedersen-Bjergaard, Ulrik and Andersen, Mikkel Porsborg and Michelsen, Jens and Imberg, Henrik and Lind, Marcus and Hallström, Sara and Lanzinger, Stefanie and Munch, Anders and Ohlendorff, Johan Sebastian and Gerds, Thomas Alexander and Torp-Pedersen, Christian and REDDIE Consortium, REDDIE Consortium},
  title = {Sustained glucagon‐like peptide‐1 receptor agonist treatment improves glycemic control and reduces all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitors: A real‐world target trial emulation in type 2 diabetes},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {5},
  pages = {3974--3984},
  doi = {10.1111/dom.70581}
}
Kostenlos starten →